Chemotherapy Before and After Mastectomy in Stage III Breast Cancer

Perloff, Marjorie; Lesnick, Gerson

doi:10.1001/archsurg.1982.01380310005002

Cited by 65 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this retrospective review are in agreement with those of other authors regarding the heterogeneity and the highly different prognoses for different subgroups of stage I11 breast cancer patients (5, 16,19,22,27,28). The most striking finding of the present study was the great difference between nodal groups pNO, pN1 and pN2-3 with respect to relapse-free survival and survival.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Prognostic Significance of Lymph Node Status in Stage III Breast Cancer

Baldursson¹

1988

Acta Oncologica

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

“…Consequently, the majority of these patients probably harbor micrometastases at the time of primary treatment. This has led many investigators to combine chemotherapy with surgery andlor irradiation as the initial treatment and enhanced recurrencefree interval and longer survival have been reported (1, 3, 6, 8, 11, 19,22,27,29,32,36).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Lymph Node Status in Stage III Breast Cancer

Baldursson¹

1988

Acta Oncologica

View full text Add to dashboard Cite

“…References [1][2][3][4] Studies comparing neoadjuvant with adjuvant chemotherapy have shown that while disease-free, progression-free and overall survival are not changed by the timing of treatment, better outcomes are seen in patients who respond to neoadjuvant therapy [5][6][7]. These results highlight a key benefit of neoadjuvant therapy, the use of response to predict long-term outcome.…”

Section: Introductionmentioning

confidence: 99%

Increase in response rate by prolonged treatment with neoadjuvant letrozole

Dixon

Renshaw

Macaskill

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose The aim of this study was to investigate the potential benefits of prolonged treatment with neoadjuvant letrozole. Patients and Methods About 182 consecutive patients have been treated in Edinburgh with neoadjuvant letrozole for 3 months or longer and 63 patients have continued on letrozole beyond 3 months. Outcomes are reported. Results Of the 63 patients who continued on letrozole, 38 patients took letrozole for more than 1 year and 23 took letrozole for more than 24 months. The median reduction in clinical volume in the first 3 months in these 63 patients was 52%. Similar reductions in median clinical volume were seen between three to 6 months (50%), 6-12 months and 12-24 months (medians 37 and 33%, respectively). At 3 months 69.8% of the 182 patients had a partial or complete response. The response rate increased to 83.5% with prolonged letrozole treatment. Continuing letrozole beyond 3 months increased the number of women who initially required mastectomy or had locally advanced breast cancer who were subsequently suitable for breast conserving surgery from 60% (81/134) at 3 months to 72% (96/134). Thirty-three women remain on letrozole alone (man age at diagnosis 83 years) and at 3 years the median time to treatment failure has not been reached. Conclusion Continuing letrozole in responding patients beyond 3-4 months achieves further clinical reduction in tumour size. For elderly women with a short life expectancy letrozole alone may provide long-term disease control.Keywords Breast conserving surgery Á Endocrine therapy Á Neoadjuvant Á Letrozole Á Large operable and locally advanced breast cancer

show abstract

“…Large operable and locally advanced breast cancers continue to be common despite the introduction of breast screening programmes [1]. Neoadjuvant (pre-operative or primary) systemic chemotherapy often results in locally advanced and unresectable primary breast tumours becoming operable [2,3]. Neoadjuvant hormone therapy has also been used more recently to shrink large operable breast cancers that would normally require mastectomy allowing them subsequently to be treated with breast-conserving surgery [4][5][6][7][8][9][10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%